Classification
Product TypeIngredient
Product FormBulk chemical (ubidecarenone/coenzyme Q10) and finished oral supplement preparations
Industry PositionNutraceutical ingredient and dietary supplement input
Market
Coenzyme Q10 (ubidecarenone) in Mexico is primarily relevant as an input for, or component of, finished “suplementos alimenticios” sold in oral dosage forms. Mexico’s tariff schedule explicitly classifies Coenzyme Q10 under TIGIE code 2914.62.01, with import duty listed as Exento in the tariff text. Market access risk is dominated by health-regulatory classification and claims control: COFEPRIS guidance emphasizes supplements are not medicines and must not present therapeutic, preventive, or curative claims. For cross-border supply, COFEPRIS operates a sanitary “permiso sanitario previo de importación” mechanism for certain foods/supplements listed under the health-regulation agreement referenced by the agency.
Market RoleImport-oriented dietary supplement ingredient and finished supplement market
Domestic RoleUsed in the dietary supplement category (“suplemento alimenticio”) for oral consumption; products must be positioned to complement dietary intake and not to treat/cure/prevent disease
Market Growth
Specification
Primary VarietyUbidecarenone (Coenzyme Q10; ubiquinone)
Compositional Metrics- Importer and manufacturer quality files commonly include a lot-specific Certificate of Analysis (identity and assay/purity) aligned to the declared ingredient and label.
Grades- TIGIE/HS chemical classification: 2914.62 (Coenzyme Q10) for the active substance in bulk
Packaging- COFEPRIS describes acceptable oral presentation forms for supplements (e.g., cápsula, polvo, tableta, jarabe, solución/suspensión) and indicates certain non-oral/other-category forms (e.g., confitería, parches, inyectables) are not permitted for the supplement category.
Supply Chain
Value Chain- Overseas CoQ10 manufacturer (bulk ubidecarenone) → Mexican importer of record → health-regulatory import authorization/permit step with COFEPRIS if applicable → customs clearance under TIGIE 2914.62.01 → domestic distribution to supplement manufacturers/packers or retail importers
Freight IntensityLow
Transport ModeMultimodal
Risks
Regulatory Compliance HighA key deal-breaker risk is COFEPRIS non-compliance driven by product classification and claims: supplements in Mexico must not present therapeutic/preventive/curative claims, and borderline products may be reclassified (e.g., as a medicine/remedy category), which can block import processing, trigger seizures/administrative actions, or force relabeling.Run a pre-market claims/label review against COFEPRIS supplement guidance; use the COFEPRIS “consulta de clasificación” process for borderline cases; ensure formula, intended use, and label text are consistent with the supplement category and supported by a complete documentary file (including CoA).
Documentation Gap MediumMismatch between quantitative formula, ingredient naming (CoQ10/ubidecarenona), CoA, and labeling can drive clearance delays or rejection during sanitary review and customs processing.Standardize nomenclature and units across CoA, invoice, and label; keep a controlled document set per SKU/lot and validate against the importer’s COFEPRIS/customs checklist before shipment.
Market Surveillance MediumCOFEPRIS emphasizes sanitary surveillance and encourages reporting of irregular supplement commercialization; non-compliant advertising or channel practices can trigger enforcement actions and business interruption.Implement compliant marketing controls (especially for online listings), authorized-distributor policies, and a rapid response SOP for COFEPRIS inquiries or market surveillance events.
Labor & Social- Illicit or irregular commercialization of dietary supplements is a documented enforcement focus in Mexico; brand owners and importers face reputational and enforcement risk if product is diverted into informal channels or marketed with prohibited claims.
FAQ
¿Cuál es la fracción arancelaria TIGIE de México para la Coenzima Q10 (ubidecarenona)?La TIGIE de México lista “Coenzima Q10 (ubidecarenona (DCI))” en la fracción 2914.62.01. En el texto de la tarifa, el impuesto de importación se muestra como Exento para esa fracción.
¿Cuál es el principal riesgo regulatorio al importar o vender productos con CoQ10 en México como suplemento?El riesgo más crítico es el de cumplimiento con COFEPRIS por clasificación y claims: COFEPRIS indica que los suplementos alimenticios no son para tratar, curar o prevenir enfermedades, por lo que declaraciones terapéuticas pueden volver el producto no conforme o provocar reclasificación y problemas en importación/comercialización.
¿Qué tipo de presentación acepta COFEPRIS para un “suplemento alimenticio” en México?COFEPRIS describe que los suplementos pueden presentarse en formas orales como cápsula, polvo y tabletas (entre otras formas farmacéuticas por vía oral contempladas en la Farmacopea de los Estados Unidos Mexicanos) y señala que no se permiten presentaciones propias de otras categorías, como confitería, parches o inyectables.